CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM).
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Asim Amin
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Bristol-Myers Squibb; Genentech
Yvonne M. Saenger
Research Funding - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Gregory K. Pennock
Honoraria - Bristol-Myers Squibb
Troy H. Guthrie
No relevant relationships to disclose
April K. Salama
Consultant or Advisory Role - Bristol-Myers Squibb (U); Roche/Genentech
Research Funding - Bristol-Myers Squibb
Lawrence E. Flaherty
Consultant or Advisory Role - Genomic Health; GlaxoSmithKline; Merck; Roche/Genentech; SMS Pharmaceuticals
Honoraria - Roche/Genentech
Henry B. Koon
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Bristol-Myers Squibb; Genentech
David H. Lawson
Consultant or Advisory Role - Bristol-Myers Squibb; Roche/Genentech
Montaser F. Shaheen
No relevant relationships to disclose
Agnes Balogh
Employment or Leadership Position - Bristol-Myers Squibb
Cyril Konto
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Steven O'Day
Consultant or Advisory Role - Bristol-Myers Squibb (U); Roche (U)
Honoraria - Bristol-Myers Squibb; Roche
Research Funding - Bristol-Myers Squibb; Roche